Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 136.38 USD -0.99% Market Closed
Market Cap: 8.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 196.93 USD with a low forecast of 154.53 USD and a high forecast of 303.45 USD.

Lowest
Price Target
154.53 USD
13% Upside
Average
Price Target
196.93 USD
44% Upside
Highest
Price Target
303.45 USD
123% Upside

ASND Last Price Targets
Ascendis Pharma A/S

The latest public price target was made on Sep 23, 2024 by Tazeen Ahmad from Bank of America Securities , who expects ASND stock to rise by 40% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Tazeen Ahmad
Bank of America Securities
191 USD
Upside 40%
3 months ago
Sep 23, 2024
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
StreetInsider
Leland Gershell
Oppenheimer
190 USD
Upside 39%
3 months ago
Sep 17, 2024
Ascendis Pharma (ASND) PT Raised to $190 at Oppenheimer
StreetInsider
Derek Archila
Wells Fargo
289 USD
Upside 112%
3 months ago
Sep 17, 2024
Ascendis Pharma price target raised to $289 from $264 at Wells Fargo
TheFly
Gavin Clark-Gartner
Evercore ISI
205 USD
Upside 50%
3 months ago
Sep 17, 2024
Ascendis Pharma price target raised to $205 from $191 at Evercore ISI
TheFly
David Lebowitz
Citigroup
207 USD
Upside 52%
3 months ago
Sep 17, 2024
Ascendis Pharma price target raised to $207 from $178 at Citi
TheFly
Paul Choi
Goldman Sachs
200 USD
Upside 47%
3 months ago
Sep 16, 2024
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
StreetInsider
Tazeen Ahmad
Bank of America Securities
175 USD
Upside 28%
3 months ago
Sep 16, 2024
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
StreetInsider
David Lebowitz
Citigroup
178 USD
Upside 31%
3 months ago
Sep 13, 2024
Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
StreetInsider
Leland Gershell
Oppenheimer
180 USD
Upside 32%
3 months ago
Sep 5, 2024
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
StreetInsider
Kelly Shi
Jefferies
196 USD
Upside 44%
4 months ago
Aug 13, 2024
Ascendis Pharma price target raised to $196 from $174 at Jefferies
TheFly
Alex Thompson
Stifel Nicolaus
200 USD
Upside 47%
6 months ago
May 30, 2024
Stifel Starts Ascendis Pharma (ASND) at Buy
StreetInsider
Vikram Purohit
Morgan Stanley
140 USD
Upside 3%
7 months ago
May 15, 2024
Ascendis Pharma (ASND) PT Raised to $140 at Morgan Stanley
StreetInsider
Josh Schimmer
Evercore ISI
191 USD
Upside 40%
9 months ago
Mar 14, 2024
Ascendis Pharma (ASND) PT Raised to $191 at Evercore ISI
StreetInsider
Show More Price Targets
Show Less Price Targets
Tazeen Ahmad
Bank of America Securities
Price Target 191 USD
Upside/Downside 40%
View Source
Leland Gershell
Oppenheimer
Price Target 190 USD
Upside/Downside 39%
View Source
Derek Archila
Wells Fargo
Price Target 289 USD
Upside/Downside 112%
View Source
Gavin Clark-Gartner
Evercore ISI
Price Target 205 USD
Upside/Downside 50%
View Source
David Lebowitz
Citigroup
Price Target 207 USD
Upside/Downside 52%
View Source
Paul Choi
Goldman Sachs
Price Target 200 USD
Upside/Downside 47%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 175 USD
Upside/Downside 28%
View Source
David Lebowitz
Citigroup
Price Target 178 USD
Upside/Downside 31%
View Source
Leland Gershell
Oppenheimer
Price Target 180 USD
Upside/Downside 32%
View Source
Kelly Shi
Jefferies
Price Target 196 USD
Upside/Downside 44%
View Source
Alex Thompson
Stifel Nicolaus
Price Target 200 USD
Upside/Downside 47%
View Source
Vikram Purohit
Morgan Stanley
Price Target 140 USD
Upside/Downside 3%
View Source
Josh Schimmer
Evercore ISI
Price Target 191 USD
Upside/Downside 40%
View Source
Show More Price Targets
Show Less Price Targets
Ascendis Pharma A/S Competitors:
Price Targets
688366
Shanghai Haohai Biological Technology Co Ltd
30% Upside
BMRN
Biomarin Pharmaceutical Inc
51% Upside
ACAD
ACADIA Pharmaceuticals Inc
52% Upside
298380
ABL Bio Inc
85% Upside
SNDX
Syndax Pharmaceuticals Inc
185% Upside
ITOS
Iteos Therapeutics Inc
244% Upside
0HS8
Caladrius Biosciences Inc
456% Upside
OPK
OPKO Health Inc
162% Upside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 55%. The projected CAGR for the next 4 years is 56%.

55%
Past Growth
56%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
196.93 USD

According to Wall Street analysts, the average 1-year price target for ASND is 196.93 USD with a low forecast of 154.53 USD and a high forecast of 303.45 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
56%

For the last 8 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 55%. The projected CAGR for the next 4 years is 56%.

Back to Top